BerGenBio ASA: Results for the Second Quarter and First Half 2019

On August 19, 2019 BerGenBio reported Results for the Second Quarter and First Half 2019 (Press release, BerGenBio, AUG 19, 2019, View Source [SID1234538837]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

-Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy

– Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those with low or no PD-L1 expression.

– Recruitment completed for second stage Phase II bemcentinib and KEYTRUDA combo trial in patients with advanced NSCLC (BGB008)

– Private placement completed, raising gross proceeds of NOK 74.2 million

– Cash and Cash equivalents at end of Q2 2019 NOK 324.4 million

– Operating loss of NOK 52.0 million in Q2 2019 (NOK 50.7 in Q2 2018) and NOK 97.1 million in H1 2019 (NOK 105.5 H2 2018).

BERGEN, Norway, Aug. 19, 2019 /PRNewswire/ — BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the second quarter and first half 2019.

A presentation and live webcast by the Company’s management will take place today at 10.00 am CEST in Oslo, please see below for details.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented:

"We are pleased to report a period of continued encouraging clinical data and validation of our lead candidate bemcentinib in our AML and NSCLC programmes. We are particularly excited by the LDAC combination data in second line AML patients.

Our focus is now on refining and preparing our late stage clinical trials in light of our recent clinical data and emerging market opportunities, as we continue to leverage our significant scientific and R&D leadership to develop this potentially transformative therapy. We are committed to progressing bemcentinib through to regulatory approval and, in turn, addressing the significant unmet need among AML and NSCLC patients in order to improve outcomes for these patients and create value for stakeholders."

Operational Highlights – second quarter and first half 2019

Acute Myeloid Leukaemia (AML)

– Preliminary Phase II clinical data from AML trial presented at EHA (Free EHA Whitepaper) 24 and ASCO (Free ASCO Whitepaper) 2019

Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows promising efficacy
6 out of 14 patients receiving LDAC combination achieved an Overall Response Rate (ORR) of 43%, with encouraging duration of response – this data is still maturing.
ORR significantly higher than previously reported/historical benchmarks (18%) with single-agent low dose cytarabine
Favourable safety profile continues to be seen in LDAC combination
Initiated preparation of expansion cohort to confirm the clinical signal from bemcentinib in combination with LDAC in elderly relapse/refractory AML patients.
Non-Small Cell Lung Cancer (NSCLC)

– New clinical data from BGB324 in NSCLC presented at ASCO (Free ASCO Whitepaper) 2019

Completed recruitment for second stage of Phase II trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC patients post chemotherapy (NCT03184571 (BGB008, cohort A)
First stage previously met efficacy endpoint, and reported encouraging median overall survival of 12.2 months
Preliminary Overall Response Rate of 40% continues to be seen in patients with AXL positive tumours including those with weak or no PD-L1 expression
Encouraging safety profile continues to be seen in combination
– Initiation of additional cohort in combination with KEYTRUDA in previously treated NSCLC patients post immunotherapy (NCT03184571, BGB008, cohort B)

Completed private placement, raising gross proceeds of NOK 74 million

Net proceeds from the Private Placement to be used to advance the Company’s clinical programs in AML and lung cancer, as well as for general corporate purposes
The Private Placement attracted strong interest from existing shareholders and new specialist institutional investors
Presentation and Webcast Details

A presentation by BerGenBio’s senior management team will take place today at 10:00 am CEST at:

Carnegie AS
Fjordalleen 16, 5. floor,
Aker Brygge,
Oslo

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.

Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation

On August 19, 2019 Eli Lilly and Company (NYSE: LLY) reported that it will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20th meeting of the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Barcelona, Spain (Press release, Eli Lilly, AUG 19, 2019, View Source [SID1234538865]). Remarks will focus on registrational results from the LIBRETTO-001 trial, a Phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. The webcast will begin at 7:00 p.m. Central European Time, or 1:00 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.

Spherix Urges Shareholders to Approve Purchase of CBM BioPharma, Inc. Assets at Special Meeting

On August 19, 2019 Spherix Incorporated, (NASDAQ: SPEX) a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders (Press release, Spherix, AUG 19, 2019, View Source [SID1234538988])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dear Shareholder,

In advance of our Special Meeting on September 5th, I write to update you on certain developments and to encourage you to vote in favor of the proposals recommended by the Board of Directors and set forth in the Special Meeting Proxy.

The acquisition of the CBM BioPharma, Inc. ("CBM") pharmaceutical assets is an integral step in building Spherix into a cutting edge pharmaceutical company. It also builds upon the success we have already realized as a part of the Company’s transformation. Two years ago, Spherix made an investment in Hoth Therapeutics, Inc., which is now estimated to be worth over $10,000,000. In our effort to deliver value to our shareholders and to continue the transformation at Spherix, the Board intends to propose a special dividend of One Hundred Thousand shares (100,000) of Hoth stock. Effectuating the dividend is contingent upon obtaining the necessary votes for the CBM acquisition at the Special Meeting to be held on September 5th. The dividend will be paid upon the consummation of the transaction with CBM to shareholders of record prior to the date of such consummation. Upon closing the acquisition of the CBM assets, the Company expects to focus its efforts on growing and developing its portfolio.

The proposed Hoth dividend represents over $500,000 of value at today’s stock price. Should Spherix not receive the necessary votes to acquire the CBM assets on September 5th, it is unlikely that the Hoth dividend will be declared. The Company would instead retain this stock to use as a valuable resource for other corporate and strategic matters.

There are three ways to vote your shares of Spherix, each only taking a few moments:

By Telephone – Stockholders in the United States can submit their vote by calling the toll-free number indicated on the Special Proxy you received by mail; please have your control number located on the enclosed vote instruction form available when calling;
By Internet – Stockholders can submit their vote via internet at www.proxyvote.com; please have the control number located on the enclosed vote instruction form available; or
By Mail – Stockholders can vote by mail by signing, dating and returning the enclosed vote instruction form in the postage-paid envelope provided.
If you need any assistance in voting your shares or have questions regarding the special meeting of stockholders, please contact Spherix’s proxy solicitor, MacKenzie Partners, Inc., at (800) 322-2885 (toll-free) or (212) 929-5500 (collect), or email at [email protected].

I thank you for your continued support and investment in our Company. We believe with conviction that we are taking the right steps to drive shareholder value, make sound investment decisions, and return capital to shareholders when appropriate.

Sincerely,

Anthony Hayes

HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019

On August 19, 2019 HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders, reported plans to change its name to INHIBITOR Therapeutics as well as a change to the ticker symbol for common and preferred stock to "INTI" from "HPPI (Press release, HedgePath Pharmaceuticals, AUG 19, 2019, View Source [SID1234538866])." Both the corporate name change and ticker symbol change are expected to be effective with the opening of trading on August 20, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In conjunction with the corporate name change, INHIBITOR will launch a new website (www.inhibitortx.com) to showcase INHIBITOR’s vision and development strategy for SUBA-Itraconazole, a proprietary formulation of the FDA approved anti-fungal drug itraconazole designed to enable improved bioavailability compared to conventional itraconazole when used as an anti-cancer treatment, as well as novel compounds that inhibit upstream targets of the Hedgehog Pathway as treatments for cancer and non-cancerous proliferation disorders.

"Changing our name to INHIBITOR Therapeutics marks an important point of inflection for our company as we are now positioned to capitalize on several business and clinical development initiatives, offering potential catalysts for multiple value-building events during 2019 and 2020," stated Nicholas J. Virca, President and Chief Executive Officer of INHIBITOR. "In the near-term, following a pre-IND (Investigational New Drug) meeting with the Food and Drug Administration (FDA) in April this year, INHIBITOR has secured an End of Phase 2 Meeting (EOP2) with FDA scheduled for the fourth quarter of 2019 to finalize our clinical protocol and statistical analysis plan as we prepare to submit our IND application to study SUBA-Itraconazole in patients with late-stage prostate cancer. Upon IND clearance, we plan to initiate a multi-center, randomized, double-blind, placebo-controlled Phase 2b clinical trial in men with metastatic castrate-resistant prostate cancer (mCRPC) in 2020. Additionally, in 2020, we plan to hold discussions with the FDA to advance our Phase 2b clinical program to study SUBA-Itraconazole in patients with late-stage lung cancer."

Virca continued, "We are also excited to report the signing of a renewal, for an additional year, of an expanded, exclusive worldwide option agreement with the University of Connecticut to initiate pre-clinical testing in basal cell carcinoma using novel compounds (itraconazole analogues) designed to inhibit specific protein targets of the Hedgehog Pathway. We believe this technology has significant potential and could become a platform for targeting multiple cancerous and non-cancerous proliferation disorders."

About SUBA-Itraconazole

SUBA-Itraconazole is a patented formulation of itraconazole designed to enable improved absorption and significantly reduced variability compared to generic itraconazole. Research suggests that these properties offer the potential to provide reduced intra- and inter-patient variability, enable a more predictable clinical dose response, and reduce the active drug quantity required to deliver therapeutic levels into the bloodstream.

SUBA-Itraconazole is manufactured by Mayne Pharma under current Good Manufacturing Practice standards for INHIBITOR’s use in clinical trials. An affiliate of Mayne Pharma is INHIBITOR’s majority stockholder and the licensor of the SUBA-Itraconazole technology.

About University of Connecticut Itraconazole Analogues

The itraconazole analogues, which are being developed by Dr. M. Kyle Hadden, Associate Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences at the University of Connecticut, have modifications to particular regions of the itraconazole scaffold. The patents and patent applications include compositions of matter claims covering the itraconazole analogues and method claims covering their use for the treatment of cancer. Data from Dr. Hadden’s laboratory suggest that certain of these analogues maintain potent Hedgehog Pathway inhibition while exhibiting improved pharmacokinetic parameters and reduced off-target side effects sometimes associated with itraconazole. Initial testing efforts are focused on BCC tumor inhibition.

WuXi Biologics Reports Outstanding Interim Results

On August 19, 2019 WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group," stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, reported its unaudited interim results for the six months ended June 30, 2019 (Press release, WuXi Biologics, AUG 19, 2019, View Source [SID1234538867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First-Half 2019 Financial Highlights

Strong revenue growth of 52.4% y-o-y to RMB1,607.1 million.
Gross profit increased by 61.8% y-o-y to RMB671.0 million, with gross profit margin up 250 basis points to 41.8% mainly due to (i) strong business growth with the increase of number of integrated projects; (ii) the improved operational efficiency of the Group, in particular, the fast ramp-up of MFG3; and (iii) more milestone payments received.
Net profit and adjusted net profit grew 80.1% and 75.8% y-o-y to RMB449.5 million and RMB521.5 million, respectively.
Net profit margin and adjusted net profit margin were 28.0% and 32.4%, respectively, both up 430 basis points y-o-y, due to strong growth in revenue, solid cost control and business operation efficiency enhancement, and more milestone payments.
Diluted EPS increased by 78.9% from RMB0.19 to RMB0.34.
Adjusted diluted EPS increased by 69.6% from RMB0.23 to RMB0.39.
First-Half 2019 Operational Highlights

The number of ongoing integrated projects increased from 187 as of June 30, 2018, to 224 as of June 30, 2019, with late-phase projects increasing from 10 to 15.
Total backlog grew significantly from US$3,639 million as of December 31, 2018 to US$4,630 million as of June 30, 2019. Our potential upcoming milestone backlog surged from US$2,006 million as of December 31, 2018 to US$2,894 million as of June 30, 2019, mainly driven by signing more WuXiBodyTM projects.
WuXi Vaccines signed letter of intent (LOI) for a 20-year vaccine manufacturing contract valued over US$3 billion with a global vaccine leader, demonstrating our technical strength, global premier quality, and transferable skills from biologics to vaccines.
WuXiBodyTM continued to be widely adopted by global and domestic customers, signed 8 licensing agreements with 5 partners in 1H 2019, which will potentially contribute more milestone and royalty revenues.
The Group successfully completed the first FDA routine GMP inspection, which demonstrates continuous commitment and strong expertise in meeting global compliance requirements.
Our manufacturing facility expansion is on track. MFG4, the first facility in China to use 4,000L disposable bioreactor and DP4, the first robotic sterile filling facility for biologics in China are both GMP released in July.
The Group continued to attract and retain talents and build one of the largest biologics development teams globally, while our retention rate is higher than 95%, significantly higher than the industry average.
WuXi Biologics continues the strong growth trend. The number of integrated projects and backlog kept expanding meanwhile our vaccine business made great progress only one year after its launch. All our global manufacturing capacity expansion is on track, laying a solid foundation to meet strong demands in the future. In addition, we estimate that our total employee number will reach around 5,600 by the end of 2019. The Group’s innovative proprietary technology platforms led the industry innovation trend, better enabled our partners and further enhanced the Group’s mission of accelerating and transforming biologics discovery, development and manufacturing.

Robust Revenue Growth Continued, Gross Margin and Net Profit Margin Expanded

In 1H 2019, WuXi Biologics continued to deliver robust revenue growth of 52.4% y-o-y to RMB1,607.1 million, further demonstrating the successful implementation of our "Follow-the-Molecule" strategy. Our net profit and adjusted net profit grew 80.1% and 75.8% y-o-y to RMB449.5 million and RMB521.5 million, respectively. Meanwhile the gross margin, net profit margin, and adjusted net profit margin all expanded substantially and achieved record-highs. Our innovative technology platforms have been endorsed by the industry, and started to contribute more milestone revenue, which have improved the margins in this period.

The Group continued to gain more market share and win trust from customers. The number of ongoing integrated projects increased to 224 as of June 30, 2019, with late-phase projects increasing to 15. The backlog surged to US$4,630 million as of June 30, 2019 with potential upcoming milestone backlog surging to US$2,894 million as of June 30, 2019, demonstrating our technology platforms are adopted by more customers and will contribute more future revenue.

Reinforce Technology Innovation, WuXiBodyTM Widely Adopted by Customers

As the Group continues to reinforce its efforts in technology innovation, the R&D expenses have reached 6.8% of the total revenue in 1H 2019. WuXi Biologics is leveraging innovative technologies to optimize the entire spectrum of services offered to global biologics industry. The Group expects the strong momentum to continue, driven by the growing expenditures in R&D for biologics worldwide, as it expands its customer base and increases revenue from each integrated project as well as milestone and royalty fees.

Since the launch of WuXiBodyTM, this platform has been quickly adopted by global and domestic partners with 5 new partners and 8 projects in 1H 2019. The Group has showed its capability in expediting bispecific development and cost reduction by successfully entering into multiple strategic collaborations. The WuXiBodyTM platform will be another growth driver which contributes more milestone payments and future royalties as well as adds more integrated projects into our pipeline of "Follow-the-Molecule" strategy.

WuXi Vaccines Made Great Progress, A New Growth Engine to Drive Sustained High Growth

WuXi Vaccines, a joint venture of WuXi Biologics and Shanghai Hile Bio-Pharmaceutical, has entered into a strategic partnership via a letter of intent (LOI) with a global vaccine leader. It is estimated that the value of this 20-year manufacturing contract will be over US$3 billion. The contract is targeted to be finalized by this year with substantial revenue contribution in 2022.

This marked a huge milestone for the Group’s vaccine business which started only within one year. This partnership with a global vaccine leader, as the first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Biologics. The vaccine CDMO market, seeing huge opportunities globally and domestically as China’s regulatory reforms tightened amid increasing public awareness, is expected to be another driver of the Group’s business growth going forward.

Global Manufacturing Capacity Expansion on Track, A Demonstration of "WuXi Bio Speed"

The Group is seizing the opportunity of the booming global biologics market and has announced global manufacturing facility expansion plan since last year. The total capacity will exceed 280,000L by 2022, which will provide a robust and premier global supply chain to support the strong demands from the industry. To capture the next wave of biologics, the Group has also announced to expand construction of a new integrated biologics conjugation solution center for ADCs, which will further enhance the technical capabilities and manufacturing capacities in the fast-growing bioconjugation field.

All the Group’s construction projects are on track, demonstrating the "WuXi Bio Speed". The Ireland site will be GMP ready in 2021 and support the demands from European and US markets. Furthermore, MFG4 and DP4 are both GMP released in July. It took only 13 months for MFG4 and 12 months for DP4 from completing design to GMP-release of the facility, further demonstrating "WuXi Bio Speed".

Completed First FDA Routine GMP Inspection, Another Demonstration of "WuXi Bio Quality"

In 1H 2019, the Group has also successfully completed a seven-day FDA surveillance inspection for the production of Trogarzo, the first routine GMP inspection since product approval. The completion of the inspection further endorses WuXi Biologics’ proven quality system and solid reputation as a leading global biomanufacturing player, demonstrating that "WuXi Bio Quality" has reached the highest international quality standard.

Dr. Chris Chen, CEO of WuXi Biologics, said, "We are excited about the extraordinary performance achieved in 1H 2019. WuXi Biologics continued to gain more market share from the booming biologics outsourcing market due to our advanced technology platforms, premier quality system and excellent track record. We are delighted to see that the number of integrated projects and total backlog have both increased substantially, showcasing the success of ‘Follow-the-Molecule’ strategy and providing clear visibility for our future growth. We also keep exploring new business opportunities as the vaccine business has made great progress and WuXiBodyTM platform has been widely adopted by the industry. Through these new growth engines, the Group will engage more in the global biologics innovation and enable more strategic partners."

Dr. Chris Chen, further commented, "As a global leading enabling platform, WuXi Biologics continues to shorten the timeline from DNA to IND, expedites product development at record speed. We have sufficient capacity to start any project within 4 weeks. Besides, our expanding global footprints are all on track and the ‘Global Dual Sourcing within WuXi Bio’ strategy will ensure our partners’ commercial product supply as well as securing more commercial manufacturing contracts for the Group. We already have 58 first-in-class projects in pipeline, demonstrating our strong capabilities to enable global innovative partners. With the cutting-edge platforms, we strive to enable partners worldwide and we have seen exceptional growth from three major regions, especially the U.S., our largest market, which maintained high growth despite geopolitical uncertainties. Our EU market has sustained over 185% CAGR growth over the past five years. Throughout 1H 2019, we drove a superior business execution. Looking ahead, we are confident that the strong growth momentum will continue and solidify our leading position."

Dr. Ge Li, Chairman of WuXi Biologics, concluded: "The booming biologics industry is full of opportunities and we are well prepared for it. We will continue to accelerate and transform biologics industry and provide a robust global supply chain with premium quality. The ecosystem we are building will enable our customers and partners to discover, develop and manufacture more drugs to benefit patients worldwide."

2019 Interim Results

The Group’s revenue increased by 52.4% y-o-y to RMB1,607.1 million in 1H 2019. The major revenue growth drivers were: (i) enhancement of core competitiveness contributing to more market share and steady growth in the number of integrated projects; (ii) the Group’s innovative proprietary technology platforms have been more adopted in the industry and; (iii) the success of "Follow-the-Molecule" strategy.

Gross Profit increased by 61.8% to RMB671.0 million in 1H 2019. The Group’s gross profit margin increased from 39.3% in the first half of 2018 to 41.8% of same period this year. The improvement was driven by the following factors: (i) the Group’s strong business growth, along with the rapid increase in its number of integrated projects; (ii) the improved operational efficiency, in particular, the fast ramp-up of MFG3; (iii) more milestone payments received.

During the Reporting Period, Net Profit surged by 80.1% y-o-y to RMB449.5 million in 1H 2019, higher than 78% announced in Positive Profit Alert announcement, with net profit margin up 430 basis points to 28.0% in 1H 2019. The significant increase in net profit margin was primarily attributable to (i) steady increase in the number of integrated projects and as a result, strong growth in revenue; (ii) solid cost control and business operation efficiency enhancement.

Adjusted Net Profit, by excluding the impact of: (i) foreign exchange gains or losses; (ii) share-based compensation, our adjusted net profit increased by 75.8% y-o-y to RMB521.5 million in 1H 2019, and adjusted net profit margin went up 430 basis points from 28.1% in the first half of 2018 to 32.4% of same period this year.

Basic and Diluted EPS were RMB 0.37 and RMB 0.34, respectively. Diluted EPS increased by 78.9% y-o-y.

Adjusted Diluted EPS increased by 69.6% y-o-y to RMB 0.39.